The study will compare NHS and social data to track long term impact of childhood blood disorders.

A single one-time gene therapy could free patients with α-thalassemia, a rare and debilitating blood disorder, from the burden of lifelong transfusions. A single one-time gene therapy could free ...

WASHINGTON — The Food and Drug Administration has approved the first drug treatment for pediatric patients 12 and older with a rare blood disorder. The treatment for acquired thrombotic ...

Our inbox has been flooded with emails from viewers and readers who want to share their personal stories — people who want to ...

Novo Nordisk said it would take over a drug under development to treat rare blood and kidney disorders from Nasdaq-listed biopharmaceutical firm Omeros for up to $2.1 billion. Under the asset purchase ...

PharmaEssentia will spend $46 million to build a new manufacturing facility in Puerto Rico. The move forms part of the ...